This week’s News Flash highlights five clinically useful publications appearing in the August literature. The emphasis is on treatment persistence, body composition, oral obesity medications, and practical decisions about treatment goals.

1. Why Do Patients Stop GLP-1 Medications? A New National Survey Adds Real-World Detail

Evidence status: Peer-reviewed national survey

A newly published U.S. survey examined discontinuation of GLP-1 receptor agonists among adults and provides a useful real-world view of why treatment does not always continue as planned. The study is important because persistence is a prerequisite for obtaining and maintaining the benefits seen in clinical trials.

Conclusion of the study: “In this national survey, most US adults who stopped GLP-1 RAs did so within 6 months because of cost, adverse effects, lack of coverage, or having achieved a weight loss goal. Differences in coverage, costs, and sourcing are modifiable targets that may decrease high rates of GLP-1 RA discontinuation.”

Survey data cannot establish cause and effect, and self-reported treatment histories have limitations. Even so, the findings reinforce that discontinuation is not a single clinical phenomenon: affordability, access, adverse effects, treatment expectations, and other practical factors can all influence whether patients remain on therapy.

Belite Commentary

For a weight-management practice, persistence should be treated as a clinical outcome rather than an administrative detail. When treatment is interrupted, the reason matters. A patient stopping because of nausea requires a different strategy from a patient stopping because insurance coverage changed.

The practical implication is to ask about barriers early and repeatedly—before a patient simply disappears from treatment. Dose adjustment, slower escalation, alternative medications, and advance planning for insurance or cost problems may prevent avoidable interruptions.

Primary source: DiStefano MJ, et al. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026;32(8):903-910. PMID 42504813. PubMed  |  DOI

2. GLP-1–Based Weight Loss Changes Both Fat and Lean Mass: New Analysis Compares the Available Evidence

Evidence status: Peer-reviewed systematic review and network meta-analysis of randomized trials

A new network meta-analysis compared direct body-composition measurements from randomized trials of GLP-1–based medications in adults with overweight or obesity, with or without type 2 diabetes. The analysis confirms an important point: pharmacologic weight loss is predominantly fat loss, but lean mass also declines.

The exact amount of lean-mass change differed across agents and trials. Because network meta-analysis combines direct and indirect comparisons, the rankings should not be interpreted as if every medication had been tested head-to-head under identical conditions.

Study Conclusion: “GLP-1RAs substantially improve body composition-related excess adiposity, but unfavourable effects on lean mass were observed, particularly at high doses.”

Belite Commentary

The clinical goal is not simply to minimize the number on the scale. It is to reduce excess adiposity while preserving function and as much metabolically useful lean tissue as possible.

For patients—particularly older adults or those starting with low muscle mass—adequate protein intake, resistance exercise, avoidance of unnecessarily severe caloric restriction, and attention to functional strength remain sensible components of GLP-1 treatment. The study does not establish a need for routine body-composition scanning in every patient.

Primary source: Wachiraphansakul N, et al. Comparative Effects of Individual GLP-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition… Diabetes Obes Metab. 2026;28(8):7018-7038. PMID 42209204. PubMed  |  DOI

3. Oral Semaglutide vs. Orforglipron: An Indirect Comparison Suggests Both Could Become Important Pill Options

Evidence status: Peer-reviewed population-adjusted indirect treatment comparison; not a head-to-head randomized trial

Investigators compared oral semaglutide 25 mg with orforglipron 36 mg using a population-adjusted indirect treatment comparison. Both are oral approaches to obesity treatment, but they differ pharmacologically: oral semaglutide is a peptide GLP-1 receptor agonist, whereas orforglipron is a nonpeptide small-molecule GLP-1 receptor agonist.

Study Conclusion: “In this ITC, oral semaglutide 25 mg was associated with greater body weight loss and fewer discontinuations due to any AEs and due to GI AEs compared with orforglipron 36 mg. These findings provide insight into the comparative effectiveness and tolerability in the absence of head-to-head clinical trials.”

The analysis is useful for anticipating how future oral options might compare, but it is inherently less certain than a randomized head-to-head trial. Differences between the source trials can remain even after statistical adjustment.

Belite Commentary

The larger story is the maturation of oral obesity pharmacotherapy. If effective oral agents become broadly available, some patients who decline injections—or who have difficulty maintaining injectable treatment—may have additional choices.

The comparative numbers should not be used to declare a winner. Direct randomized trials, long-term safety data, regulatory status, dosing instructions, tolerability, cost, and adherence will matter more than an indirect ranking.

Primary source: Michalak W, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes Obes Metab. 2026;28(8):7247-7256. PMID 42225305. PubMed  |  DOI

4. Could an Oral Semaglutide Tablet Approach Injectable Wegovy-Level Weight Loss?

Evidence status: Peer-reviewed indirect treatment comparison; not a direct randomized comparison

A separate analysis compared oral semaglutide 25 mg with injectable semaglutide 2.4 mg using data from different clinical-trial populations. The results suggest that high-dose oral semaglutide may be capable of weight loss in the range achieved with injectable semaglutide.

However, this was not a trial in which patients were randomly assigned to the oral versus injectable formulation. Cross-trial differences and statistical assumptions limit how confidently the two formulations can be compared.

Belite Commentary

For patients, the important development is choice. An effective tablet could remove injection reluctance for some people, although oral semaglutide has administration requirements that may affect convenience and adherence.

Study Conclusion: “This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.”

Until direct comparative evidence is available, clinicians should avoid presenting the oral and injectable formulations as proven equivalents. Effectiveness in routine practice depends on whether patients can take the medication correctly and consistently.

Primary source: Plotkin M, et al. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes Obes Metab. 2026;28(8):7237-7246. PMID 42225300. PubMed  |  DOI

5. How Much Weight Should a Patient Lose? Experts Argue That the Goal Should Be Health, Not the Lowest Possible Number

Evidence status: Peer-reviewed expert review / clinical perspective

Highly effective obesity medications have created a new clinical question: when should active weight loss stop? A new review examines the concept of healthy weight loss and target weight in an era when medications can produce reductions that were previously difficult to achieve without surgery.

The authors emphasize that a target should not be defined by body weight alone. Body composition, muscle function, nutritional status, age, comorbidities, and the point at which additional loss offers diminishing health benefit all become relevant.

Belite Commentary

This is particularly important as treatment becomes more effective. More weight loss is not automatically better weight loss. A patient who has reached substantial metabolic benefit but is losing strength, lean tissue, or nutritional reserve may need a different goal than a younger patient with substantial residual adiposity.

The practical endpoint should be individualized: meaningful health improvement, sustainable eating and activity, preserved function, acceptable tolerability, and a maintenance strategy—not simply pursuit of the lowest achievable scale weight.

Primary source: Bosy-Westphal A, et al. Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity. J Cachexia Sarcopenia Muscle. 2026;17(4):e70334. PMID 42455525. PubMed  |  DOI

Belite Clinical Takeaway

This week’s literature emphasizes a transition in obesity medicine from asking only “How much weight can this drug produce?” to asking more clinically useful questions: Can the patient stay on treatment? What is happening to fat and lean tissue? Would an oral option improve adherence? And when has a patient lost enough weight to shift from active loss to maintenance?

BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time

Medical Disclaimer

This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the reader’s own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.